Repligen Corporation (RGEN): Price and Financial Metrics
RGEN Price/Volume Stats
| Current price | $171.28 | 52-week high | $211.13 |
| Prev. close | $157.48 | 52-week low | $110.45 |
| Day low | $165.44 | Volume | 928,600 |
| Day high | $174.30 | Avg. volume | 538,659 |
| 50-day MA | $186.86 | Dividend yield | N/A |
| 200-day MA | $170.29 | Market Cap | 9.56B |
RGEN Stock Price Chart Interactive Chart >
Repligen Corporation (RGEN) Company Bio
Repligen Corporation develops, manufactures, and markets consumable bioprocessing products for use in the production of monoclonal antibodies and other biologic drugs. The company was founded in 1981 and is based in Waltham, Massachusetts.
Latest RGEN News From Around the Web
Below are the latest news stories about REPLIGEN CORP that investors may wish to consider to help them evaluate RGEN as an investment opportunity.
Repligen Corporation to Present at 42nd Annual J.P. Morgan Healthcare ConferenceWALTHAM, Mass., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present at the 42nd Annual J.P. Morgan Healthcare conference being held January 8-11 in San Francisco. Tony J. Hunt, Chief Executive Officer, will present an overview of the company on Tuesday, January 9, 2024, at 2:15 p.m. PST. A live webcast of the presentation will be accessible through Repligen’s Investor Re |
Here’s Why Repligen Corporation (RGEN) Rose 13% in Q3TimesSquare Capital Management, an equity investment management company, released its “U.S. Mid Cap Growth Strategy” third-quarter investor letter. A copy of the same can be downloaded here. In the third quarter, the strategy outperformed the Russell Midcap Growth Index and returned -4.11% (net) while the index return was -5.22%. The third quarter saw a decline in […] |
Repligen's (NASDAQ:RGEN) investors will be pleased with their impressive 158% return over the last five yearsWhen you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose... |
Repligen Announces Private Convertible Transaction of $600 Million Principal Amount of 1.00% Convertible Senior Notes Due 2028 Through Exchange and New Subscription AgreementsWALTHAM, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN) today announced that on December 6, 2023, it entered into privately negotiated exchange and/or subscription agreements with certain holders of its outstanding 0.375% Convertible Senior Notes due 2024 (the “2024 Notes”) and certain new investors, pursuant to which Repligen will issue $600 million aggregate principal amount of 1.00% Convertible Senior Notes due 2028 (the “New Notes”). Approximately $309.9 million |
Why Is Exact Sciences (EXAS) Up 2.5% Since Last Earnings Report?Exact Sciences (EXAS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
RGEN Price Returns
| 1-mo | -7.36% |
| 3-mo | -7.67% |
| 6-mo | 43.23% |
| 1-year | 14.53% |
| 3-year | -21.55% |
| 5-year | 148.63% |
| YTD | -4.74% |
| 2023 | 6.20% |
| 2022 | -36.07% |
| 2021 | 38.20% |
| 2020 | 107.17% |
| 2019 | 75.39% |
Continue Researching RGEN
Want to see what other sources are saying about Repligen Corp's financials and stock price? Try the links below:Repligen Corp (RGEN) Stock Price | Nasdaq
Repligen Corp (RGEN) Stock Quote, History and News - Yahoo Finance
Repligen Corp (RGEN) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...